Intravitreal aflibercept for myopic choroidal neovascularization

To assess the use of aflibercept for the treatment of subfoveal myopic choroidal neovascularization (CNV). Thirty-two patients (33 eyes) with myopic subfoveal CNV were consecutively enrolled in this prospective open-label case series. All patients were treated with an off-label 2-mg intravitreal injection of aflibercept. After the first injection, administration of aflibercept followed an "on demand" pro re nata (PRN) regimen. The primary outcome was change in best-corrected visual acuity (BCVA) score after 12 months. Mean follow-up was 12 months, and the median number of aflibercept injections was 2.0 (range 1-4). Overall, mean BCVA improved from 0.59 +/- 0.37 logMAR at baseline to 0.38 +/- 0.33 logMAR at 12 months, a change of -0.21 +/- 0.23 logMAR (p < 0.0001), and from 70.5 +/- 18.5 to 81.1 +/- 16.4 letters, a change of 10.6 +/- 11.4 (p < 0.0001). Improvements were similar among patients irrespective of previous PDT. The Increase in BCVA was greater in younger patients (aged < 50 years) and those with baseline BCVA of aecurrency sign 75 letters. Intravitreal aflibercept in a PRN regimen is effective for the treatment of myopic CNV, with no apparent short-term safety effects. Treated eyes had BCVA gains after 12 months, with a median of two injections.